As previously reported (Eley and Tisdale, 2007), levels of both phospho-PKR (Figure 4A) and -eIF2α (Figure 4B) were significantly increased in the skeletal muscle of mice bearing the MAC16 tumour, and this was reduced down to levels found in non-tumour-bearing animals after treatment with the PKR inhibitor. The gene discussed is EIF2A; the disease is neoplasm.